1) Sender R, et al.:Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 2016;14:e1002533.
2) Qin J, et al.:A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59-65.
3) Turnbaugh PJ, et al.:An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-1031.
4) Ley RE, et al.:Microbial ecology:human gut microbes associated with obesity. Nature 2006;444:1022-1023.
5) Liu R, et al.:Gut microbiome and serum metabolome alterations in obesity and after weightloss intervention. Nat Med 2017;23:859-868.
6) Cani PD, et al.:Next-generation beneficial microbes:The Case of Akkermansia muciniphila. Front Microbiol 2017;8:1765.
7) Ferreira-Halder CV, et al.:Action and function of Faecalibacterium prausnitzii in health and disease. Best Pract Res Clin Gastroenterol 2017;31:643-648.
8) Ohkusa T, et al.:Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 2002;17:849-853.
9) Png CW, et al.:Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 2010;105:2420-2428.
10) Turnbaugh P, et al.:A core gut microbiome in obese and lean twins. Nature 2009;457:480-484.
11) Goodrich JK, et al.:Human genetics shape the gut microbiome. Cell 2014;159:789-799.
12) Morotomi M, et al.:Description of Christensenella minuta gen. nov., sp. nov., isolated from human faeces, which forms a distinct branch in the order Clostridiales, and proposal of Christensenellaceae fam. nov. Int J Syst Evol Microbiol 2012;62:144-149.
13) Ridaura VK, et al.:2013. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013;341:1241214.
14) Backhed F, et al.:The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718-15723.
15) Backhed F, et al.:Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007;104:979-984.
16) Shimizu H, et al.:Regulation of host energy metabolism by gut microbiota-derived shortchain fatty acids. Glycative Stress Res 2019;6:181-191.
17) Brown AJ, et al.:The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003;278:11312-11319.
18) Pluznick JL, et al.:Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA 2013;110:4410-4415.
19) Greiner TU, et al.:Microbial regulation of GLP-1 and L-cell biology. Mol Metabol 2016;5:753-758.
20) Samuel BS, et al.:Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA 2008;105:16767-16772.
21) Tolhurst G, et al.:Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012;61:364-371.
22) Madsen, MSA, et al.:Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice. Sci Rep 2019;9:15582.
23) Wang TJ, et al.:Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453.
24) Magnusson M, et al.:A diabetes-predictive amino acid score and future cardiovascular disease. Eur Heart J 2013;34:1982-1989.
25) Vieira-Silva S, et al.:Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature 2020;581:310-315.
26) Yang T, et al.:Gut dysbiosis is linked to hypertension. Hypertension 2015;65:1331-1340.
27) Li J, et al.:Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 2017;5:14.
28) Jennifer L:Renal and cardiovascular sensory receptors and blood pressure regulation. Am J Physiol 2013;305:439-444.
29) Fuglsang A, et al.:Lactic acid bacteria:inhibition of angiotensin converting enzyme in vitro and in vivo. Antonie Van Leeuwenhoek 2003;83:27-34.
30) Seppo L, et al.:A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 2003;77:326-330.
31) Wilck N, et al.:Salt-responsive gut commensal modulates TH17 axis and disease. Nature 2017;551:585-589.
32) Emoto T, et al.:Analysis of gut microbiota in coronary artery disease patients:A possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb 2016;23:908-921.
33) Jie Z, et al.:The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun 2017;8:845.
34) Karlsson FH, et al.:Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 2012;3:1245.
35) Zeng X, et al.:Higher risk of stroke is correlated with increased opportunistic pathogen load and reduced levels of butyrateproducing bacteria in the gut. Front Cell Infect Microbiol 2019;9:4.
36) Zhu Q, et al.:Dysbiosis signatures of gut microbiota in coronary artery disease. Physiol Genomics 2018;50:893-903.
37) Yamashiro K, et al.:Gut dysbiosis is associated with metabolism and systemic inflammation in patients with ischemic stroke. PLoS One 2017;12:e0171521.
38) Wang Z, et al.:Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63.
39) Rath S, et al.:Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome 2017;5:54.
40) Romano KA, et al.:Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. mBio 2015;6:e02481.
41) Ahmad AF, et al.:The gut microbiome and cardiovascular disease:current knowledge and clinical potential. Am J Physiol Heart Circ Physiol 2019;317:H923-H938.
42) Andraws R, et al.:Effects of antibiotic therapy on outcomes of patients with coronary artery disease:a meta-analysis of randomized controlled trials. JAMA 2005;239:2641-2647.
43) Wang Z, et al.:Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 2015;163:1585-1595.
44) Roberts AB, et al.:Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med 2018;24:1407-1417.
45) Forslund K, et al.:Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015;528:262-266.
46) Karlsson FH, et al.:Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013;498:99-103.
47) Larsen N, et al.:Gut microbiota in human adults with type 2 diabetes differs from nondiabetic adults. PLoS ONE 2010;5(2):e9085.
48) Li Q, et al.:Implication of the gut microbiome composition of type 2 diabetic patients from northern China. Sci Rep 2020;10:5450.
49) Qin J, et al.:A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012;490:55-60.
50) Sato J, et al.:Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes. Diabetes Care 2014;37:2343-2350.
51) Pedersen H, et al.:Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 2016;535:376-381.
52) Lynch CJ, et al.:Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol 2014;10:723-736.
53) Wu H, et al.:Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 2017;23:850-858.
54) Sun L, et al.:Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med 2018;24:1919-1929.
55) Ludwig J, et al.:Nonalcoholic steatohepatitis:Mayo clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
56) Diehl AM:Nonalcoholic steatohepatitis. Semin. Liver Dis 1999;16:221-229.
57) Green RM:NASH:hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003;38:14-17.
58) Day CP, et al.:Steatohepatitis:a tale of tow "hits"? Gasteroenterology 1998;114:842-845.
59) Caussy C, et al.:A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun 2019;10:1406.
60) Chierico FD, et al.:Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated metaomics-based approach. Hepatology 2017;65:451-464.
61) Schwimmer JB, et al.:Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology 2019;157:1109-1122.
62) Loomba R, et al.:Gut Microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2017;25:1054-1062.
63) Zhu L, et al.:Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients:a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-609.
64) Boursier J, et al.:The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63:764-775.
65) Hoyles L, et al.:Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med 2018;24:1070-1080.
66) Kakiyama G, et al.:Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013;58:949-955.
67) Luther J, et al.:Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol 2015;1:222-232.
68) Baker SS, et al.:Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One 2010;5:e9570.
69) Seki E, et al.:TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med 2007;13:1324-1332.
70) Dapito DH, et al.:Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21:504-516.
71) Aranha MM, et al.:Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2008;20:519-525.
72) Ferslew BC, et al.:Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2015;60:3318-3328.
73) Yoshimoto S, et al.:Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499:97-101.
74) Jostins L, et al.:Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-124.
75) Khor B, et al.:Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-317.
76) Liu JZ, et al.:Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature genetics 2015;47:979-986.
77) Momozawa Y, et al.:IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nat Commun 2018;9:2427.
78) Sartor RB, et al.:Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 2017;152:327-339.
79) Knox NC, et al.:The gut microbiome in inflammatory bowel disease:Lessons learned from other immune-mediated inflammatory diseases. Am J Gastroenterol 2019;114:1051-1070.
80) Chehoud C, et al.:Fungal signature in the gut microbiota of pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1948-1956.
81) Hoarau G, et al.:Bacteriome and mycobiome interactions underscore microbial dysbiosis in familial Crohn's disease. mBio 2016;7:e01250-16.
82) Norman JM, et al.:Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 2015;160:447-460.
83) Sokol H, et al.:Fungal microbiota dysbiosis in IBD. Gut 2017;66:1039-1048.
84) Atarashi K, et al.:Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013;500:232-236.
85) Furusawa Y, et al.:Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013;504:446-450.
86) Sokol H, et al.:Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn's disease patients. Proc Natl Acad Sci USA 2008;105:16731-16736.
87) Rossi O, et al.:Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep 2016;6:18507.
88) Britton GJ, et al.:Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17 and RORγt+ regulatory T cells and exacerbate colitis in mice. Immunity 2019;50:212-224.
89) Atarashi K, et al.:Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science 2017;358:359-365.
90) Ni J, et al.:A role for bacterial urease in gut dysbiosis and Crohn's disease. Sci Transl Med 2017;9:eaah6888.
91) Winter SE, et al.:The dynamics of gut-associated microbial communities during inflammation. EMBO Rep 2013;14:319-327.
92) Amininejad L, et al.:Analysis of genes associated with monogenic primary immunodeficiency identifies rare variants in XIAP in patients with Crohn's disease. Gastroenterology 2018;154:2165-2177.
93) Denson LA, et al.:Clinical and genomic correlates of neutrophil reactive oxygen species production in pediatric patients with Crohn's disease. Gastroenterology 2018;154:2097-2110.
94) Wehkamp J, et al.:NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal α-defensin expression. Gut 2004;53:1658-1664.
95) Darfeuille-Michaud A, et al.:High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004;127:412-421.
96) Henke MT, et al.:Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn's disease, produces an inflammatory polysaccharide. Proc. Natl. Acad. Sci. USA 2019;116:12672-12677.
97) Limon JJ, et al.:Malassezia Is Associated with Crohn's Disease and Exacerbates Colitis in Mouse Models. Cell Host Microbe 2019;25:377-388.
98) Mallon P, et al.:Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;4:CD005573.
99) Kruis W, et al.:Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-1623.
100) Sood A, et al.:The probiotic preparation, VSL#3 induces remission in patients with mild-tomoderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:1202-1209.
101) Paramsothy S, et al.:Faecal microbiota transplantation for inflammatory bowel disease:A systematic review and meta-analysis. J Crohns Colitis 2017;11:1180-1199.
102) Paramsothy S, et al.:Multidonor intensive faecal microbiota transplantation for active ulcerative colitis:a randomised placebo-controlled trial. Lancet 2017;389:1218-1228.
103) Ishikawa D, et al.:Changes in intestinal microbiota following combination therapy with fecal microbial Transplantation and Antibiotics for Ulcerative Colitis. Inflamm Bowel Dis 2017;23:116-125.
104) Kato K, et al.:Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis:an open-label multicentre study. Aliment Pharmacol Ther 2014;39:949-956.
105) Zhu W, et al.:Precision editing of the gut microbiota ameliorates colitis. Nature 2018;553:208-211.
106) Kitamoto S, et al.:Dietary L-serine confers a competitive fitness advantage to Enterobacteriaceae in the inflamed gut. Nat Microbiol 2020;5:116-125.
107) Kostic AD, et al.:Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22:292-298.
108) Castellarin M, et al.:Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012;22:299-306.
109) Baxter NT, et al.:Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med 2016;8:37.
110) Dejea C, et al.:Bacterial oncogenesis in the colon. Future Microbiol 2013;8:445-460.
111) Feng Q, et al.:Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun 2015;6:6528.
112) Hale VL, et al.:Shifts in the fecal microbiota associated with adenomatous polyps. Cancer Epidemiol Biomarkers Prev 2017;26:85-94.
113) Lu Y, et al.:Mucosal adherent bacterial dysbiosis in patients with colorectal adenomas. Sci Rep 2016;6:26337.
114) Sears CL, et al.:Microbes, microbiota, and colon cancer. Cell Host Microbe 2014;15:317-328.
115) Yu J, et al.:Metagenomic analysis of faecal microbiome as a tool towards targeted noninvasive biomarkers for colorectal cancer. Gut 2017;66:70-78.
116) Zackular JP, et al.:The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Phila) 2014;7:1112-1121.
117) Zeller G, et al.:Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol 2014;10:766.
118) Flemer B, et al.:Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 2017;66:633-643.
119) Yachida S, et al.:Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med 2019;25:968-976.
120) Mottawea W, et al.:Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn's disease. Nat Commun 2016;7:13419.
121) Arthur JC, et al.:Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012;338:120-123.
122) Kostic AD, et al.:Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14:207-215.
123) Tsoi H, et al.:Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology 2017;152:1419-1433.
124) Yu J, et al.:The role of Parvimonas micra in intestinal tumorigenesis in germ-free and conventional APCmin/+ mice. J Clin Oncol 2019;37:531.
125) Wu S, et al.:A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016-1022.
126) Sears, CL:Enterotoxigenic Bacteroides fragilis:a rogue among symbiotes. Clin Microbiol Rev 2009;22:349-369.
127) Wu S, et al.:Bacteroides fragilis enterotoxin cleaves the zonula adherens protein, E-cadherin. Proc Natl Acad Sci USA 1998;95:14979-14984.
128) Wu S, et al.:Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology 2003;124:392-400.
129) Rubinstein MR, et al.:Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14:195-206.
130) Gur C, et al.:Binding of the Fap 2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 2015;42:344-355.
131) Abed J, et al.:Fap2 Mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe 2016;20:215-225.
132) Yu T, et al.:Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017;170:548-563.
133) Bullman S, et al.:Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358:1443-1448.
134) Routy B, et al.:Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91-97.
135) Gopalakrishnan V, et al.:Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97-103.
136) Tanoue T, et al.:A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 2019;565:600-605.
137) Strachan DP:Hay fever, hygiene, and household size. BMJ 1989;299:1259-1260.
138) Bashir ME, et al.:Toll-like receptor 4 signaling by intestinal microbes influences susceptibility to food allergy. J Immunol 2004;172:6978-6987.
139) Aumeunier A, et al.:Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS One 2010;5:e11484.
140) Cahenzli J, et al.:Intestinal microbial diversity during early-life colonization shapes longterm IgE levels. Cell Host Microbe 2013;14:559-570.
141) Oyama N, et al.:Antibiotic use during infancy promotes a shift in the TH1/TH2 balance toward TH2-dominant immunity in mice. J Allergy Clin Immunol 2001;107:153-159.
142) Olszak T, et al.:Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012;336:489-493.
143) Josefowicz SZ, et al.:Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 2012;482:395-399.
144) Russell SL, et al.:Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep 2012;13:440-447.
145) Stefka AT, et al.:Commensal bacteria protect against food allergen sensitization. Proc Natl Acad Sci USA 2014;111:13145-13150.
146) Barnetson RS, et al.:Childhood atopic eczema. BMJ 2002;324:1376-1379.
147) Metsala J, et al.:Prenatal and post-natal exposure to antibiotics and risk of asthma in childhood. Clin Exp Allergy 2015;45:137-145.
148) Stokholm J, et al.:Maternal propensity for infections and risk of childhood asthma:a registry-based cohort study. Lancet Respir Med 2014;2:631-637.
149) Saarinen UM, et al.:Breastfeeding as prophylaxis against atopic disease:prospective follow-up study until 17 years old. Lancet 1995;346:1065-1069.
150) Bunyavanich S, et al.:Early-life gut microbiome composition and milk allergy resolution. J Allergy Clin Immunol 2016;138:1122-1130.
151) Kourosh A, et al.:Fecal microbiome signatures are different in food allergic children compared to siblings and healthy children. Pediatr Allergy Immunol 2018;29:545-554.
152) Arrieta MC, et al.:Associations between infant fungal and bacterial dysbiosis and childhood atopic wheeze in a nonindustrialized setting. J Allergy Clin Immunol 2018;142:424-434.
153) Fujimura K, et al.:Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat Med 2016;22:1187-1191.
154) Arrieta MC, et al.:Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med 2015;7:307ra152.
155) Vuillermin PJ, et al.:Maternal carriage of Prevotella during pregnancy associates with protection against food allergy in the offspring. Nat Commun 2020;11:1452.
156) Mahdavinia M, et al.:Effects of diet on the childhood gut microbiome and its implications for atopic dermatitis. J Allergy Clin Immunol 2019;143:1636-1637.
157) Simonyte SK, et al.:Temporal and long-term gut microbiota variation in allergic disease:A prospective study from infancy to school age. Allergy 2019;74:176-185.
158) Candela M, et al.:Unbalance of intestinalmicrobiota in atopic children. BMC Microbiol 2012;12:95.
159) Hong PY, et al.:Comparative analysis of fecal microbiota in infants with and without eczema. PLoS One 2010;5:e9964.
160) Penders J, et al.:Gut microbiota composition and development of atopic manifestations in infancy:the KOALA Birth Cohort Study. Gut 2007;56:661-667.
161) Kim YG, et al.:Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE2. Cell Host Microbe. 2014;15:95-102.
162) Azad MB, et al.:Infant gut microbiota and food sensitization:associations in the first year of life. Clin Exp Allergy 2015;45:632-643.
163) Chen CC, et al.:Alterations in the gut microbiotas of children with food sensitization in early life. Ped Allergy Immunol 2016;27:254-262.
164) Chua HH, et al.:Intestinal dysbiosis featuring abundance of Ruminococcus gnavus associates with allergic Diseases in Infants. Gastroenterology 2018;154:154-167.
165) Fazlollahi M, et al.:Early-life gut microbiome and egg allergy. Allergy 2018;73:1515-1524.
166) Kirjavainen PV, et al.:Aberrant composition of gut microbiota of allergic infants:a target of bifidobacterial therapy at weaning?. Gut 2002;51:51-55.
167) Ling Z, et al.:Altered fecal microbiota composition for food allergy in infants. Appl Environ Microbiol 2014;80:2546-2554.
168) Nylund L, et al.:Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease. BMC Microbiol 2013;13:12.
169) McInnes IB, et al.:The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-2219.
170) du Montcel ST, et al.:New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheum 2005;52:1063-1068.
171) Gregersen PK, et al.:The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-1213.
172) Benson RA, et al.:Model answers:Rational application of murine models in arthritis research. Eur J Immunol 2018;48:32-38.
173) Hashimoto M:Th17 in animal models of rheumatoid arthritis. J Clin Med 2017;6:73.
174) Ivanov II, et al.:Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485-498.
175) Scher JU, et al.:The microbiome and rheumatoid arthritis. Nat Rev Rheumatol 2011;7:569-578.
176) Wu HJ, et al.:Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010;32:815-827.
177) Zanin-Zhorov A, et al.:Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science 2010;328:372-376.
178) Picchianti-Diamanti A, et al.:Infectious agents and inflammation:The role of microbiota in autoimmune arthritis. Front Microbiol 2018;8:2696.
179) Scher JU, et al.:Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013;2:e01202.
180) Maeda Y, et al.:Dysbiosis contributes to arthritis development via activation of autoreactive T Cells in the Intestine. Arthritis Rheumatol 2016;68:2646-2661.
181) Kishikawa T, et al.:Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Ann Rheum Dis 2020;79:103-111.
182) Gomez A, et al.:Loss of sex and age driven differences in the gut microbiome characterize arthritis-susceptible *0401 mice but not arthritis-resistant *0402 mice. PLOS ONE 2012;7:e36095.
183) Chen J, et al.:An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med 2016;8:43.
184) Mercado FB, et al.:Relationship between rheumatoid arthritis and periodontitis. J Periodontol 2001;72:779-787.
185) Wegner N, et al.:Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase:implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010;62:2662-2672.
186) Sato K, et al.:Aggravation of collagen-induced arthritis by orally administered Porphyromonas gingivalis through modulation of the gut microbiota and gut immune system. Sci Rep 2017;7:6955.
187) Pianta A, et al.:Evidence of the immune relevance of Prevotella copri, a gut microbe, in patients with rheumatoid arthritis. Arthritis Rheumatol 2017;69:964-975.
188) Marietta EV, et al.:Suppression of inflammatory arthritis by human gut-derived Prevotella histicola in humanized mice. Arthritis Rheumatol 2016;68:2878-2888.
189) Bodkhe R, et al.:The role of microbiome in rheumatoid arthritis treatment. Ther Adv Musculoskelet Dis 2019;11:1759720X19844632.
190) Picchianti-Diamanti A, et al.:Analysis of gut microbiota in rheumatoid arthritis patients:disease-related dysbiosis and modifications induced by etanercept. Int J Mol Sci 2018;19:2938.
191) Kanerud L, et al.:Effect of sulphasalazine on gastrointestinal microflora and on mucosal heat shock protein expression in patients with rheumatoid arthritis. Br J Rheumatol 1994;33:1039-1048.
192) Wekerle H:Nature plus nurture:the triggering of multiple sclerosis. Swiss Med Wkly 2015;145:w14189.
193) Sawcer S, et al.:Multiple sclerosis genetics. Lancet Neurol 2014;13:700-709.
194) Mirza A, et al.:The multiple sclerosis gut microbiota:A systematic review. Mult Scler Relat Disord 2020;37:101427.
195) Miyake S, et al.:Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV Clusters. PLoS One 2015;10:e0137429.
196) Kleinewietfeld M, et al.:Regulatory T cells in autoimmune neuroinflammation. Immunol Rev 2014;259:231-244.
197) Berer K, et al.:Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011;479:538-541.
198) Lee YK, et al.:Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2011;108:4615-4622.
199) Yokote H, et al.:NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 2008;173:1714-1723.
200) Ivanov II, et al.:The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126:1121-1133.
201) Shahi SK, et al.:Gut microbiome in multiple sclerosis:The players involved and the roles they play. Gut Microbes 2017;8:607-615.
202) Cekanaviciute E, et al.:Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci USA 2017;114:10713-10718.
203) Berer K, et al.:Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci USA 2017;114:10719-10724.
204) Ochoa-Reparaz J, et al.:A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol 2010;3:487-495.
205) Cantarel BL, et al.:Gut microbiota in multiple sclerosis:possible influence of immunomodulators. J Investig Med 2015;63:729-734.
206) Duscha A, et al.:Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism. Cell 2020;180:1067-1080.
207) Rothhammer V, et al.:Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med 2016;22:586-597.
208) Rothhammer V, et al.:Microglial control of astrocytes in response to microbial metabolites. Nature 2018;557:724-728.
209) Zelante T, et al.:Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013;39:372-385.
210) Rosen DR, et al.:Mutations in Cu_Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
211) Wu S, et al.:Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol Rep 2015;3:e12356.
212) Zhang YG, et al.:Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther 2017;39:322-336.
213) Blacher E, et al.:Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 2019;572:474-480.
214) Sandler RH, et al.:Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000;15:429-435.
215) Xu M, et al.:Association between gut microbiota and autism spectrum disorder:A systematic review and meta-analysis. Front. Psychiatry 2019;10:473.
216) Parracho HM et al.:Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol 2005;54:987-991.
217) Argou-Cardozo I, et al.:Clostridium bacteria and autism spectrum conditions:a systematic review and hypothetical contribution of environmental glyphosate levels. Med Sci (Basel) 2018;6:E29.
218) Shehata AA, et al.:The effect of glyphosate on potential pathogens and beneficial members of poultry microbiota in vitro. Curr Microbiol 2013;66:350-358.
219) Kruger M, et al.:Glyphosate suppresses the antagonistic effect of Enterococcus spp. on Clostridium botulinum. Anaerobe 2013;20:74-78.
220) Sharon G, et al.:Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell 2019;177:1600-1618.
221) Rubenstein JLR, et al.:Model of autism:increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2003;2:255-267.
223) Hsieh CY, et al.:Strengthening of the intestinal epithelial tight junction by Bifidobacterium bifidum. Physiol Rep 2015;3:e12327.
224) Plovier H, et al.:A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 2017;23:107-113.
225) Gomez-Gallego C, et al:Akkermansia muciniphila:A novel functional microbe with probiotic properties. Benef Microbes 2016;7:571-584.